DK1711164T3 - Fremgangsmåde til behandling af akut rhinosinusitis - Google Patents

Fremgangsmåde til behandling af akut rhinosinusitis

Info

Publication number: DK1711164T3
Authority: DK; Denmark
Prior art keywords: treating acute; acute rhinosinusitis; treating; disease; rhinosinusitis
Prior art date: 2004-01-21

Application number

DK05711867.1T

Other languages

English (en)

Inventor

Melvyn Bloom

Melvyn Danzig

Patricia Rohane

Heribert Staudinger

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-01-21

Filing date

2005-01-19

Publication date

2010-07-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34825945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1711164(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-01-19 Application filed by Schering Corp filed Critical Schering Corp

2010-07-19 Application granted granted Critical

2010-07-19 Publication of DK1711164T3 publication Critical patent/DK1711164T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Adhesives Or Adhesive Processes (AREA)

DK05711867.1T 2004-01-21 2005-01-19 Fremgangsmåde til behandling af akut rhinosinusitis DK1711164T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53783004P	2004-01-21	2004-01-21
PCT/US2005/002105 WO2005072704A2 (en)	2004-01-21	2005-01-19	Method of treating acute rhinosinusitis

Publications (1)

Publication Number	Publication Date
DK1711164T3 true DK1711164T3 (da)	2010-07-19

Family

ID=34825945

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05711867.1T DK1711164T3 (da)	2004-01-21	2005-01-19	Fremgangsmåde til behandling af akut rhinosinusitis

Country Status (16)

Country	Link
US (2)	US20050186144A1 (da)
EP (2)	EP2201936B1 (da)
JP (2)	JP4976139B2 (da)
AT (1)	ATE461693T1 (da)
CA (1)	CA2554064A1 (da)
CY (1)	CY1110620T1 (da)
DE (1)	DE602005020113D1 (da)
DK (1)	DK1711164T3 (da)
ES (2)	ES2340777T3 (da)
HR (1)	HRP20100208T8 (da)
MX (1)	MXPA06008240A (da)
PL (1)	PL1711164T3 (da)
PT (1)	PT1711164E (da)
RS (1)	RS51335B (da)
SI (1)	SI1711164T1 (da)
WO (1)	WO2005072704A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS51335B (en) *	2004-01-21	2011-02-28	Schering Corporation	METHOD OF TREATMENT OF ACUTE RHINOSINUSITIS
WO2008047149A1 (en) *	2006-10-19	2008-04-24	Cipla Limited	Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
TWI411121B (zh) *	2010-03-11	2013-10-01	Ind Tech Res Inst	光吸收層之製造方法及應用其之太陽能電池結構
WO2014106021A1 (en)	2012-12-27	2014-07-03	Massachusetts Eye & Ear Infirmary	Treatment of rhinosinusitis with p-glycoprotein inhibitors
US11408900B2 (en)	2016-01-15	2022-08-09	Massachusetts Eye And Ear Infirmary	Secreted P-glycoprotein is a non-invasive biomarker of chronic rhinosinusitis
EP4167988A4 (en) *	2020-06-21	2024-07-03	Massachusetts Eye and Ear Infirmary	Combination verapamil and mometasone therapy for the treatment of chronic rhinosinusitis
JP2024049405A (ja) *	2021-02-22	2024-04-10	興和株式会社	新規吸入剤

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE8790T1 (de)	1981-02-02	1984-08-15	Schering Corporation	Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
US4731447A (en) *	1985-05-13	1988-03-15	Schering Corporation	Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4873335A (en)	1986-03-12	1989-10-10	Schering Corporation	3-phenethyl-2-benzene-amides or aza-derivatives thereof
WO1992022287A1 (en) *	1991-06-10	1992-12-23	Schering Corporation	Non-chlorofluorocarbon aerosol formulations
DE69208660T2 (de)	1991-06-10	1996-07-11	Schering Corp., Kenilworth, N.J.	Fluorchlorkohlenwasserstoffreie aerosolformulierungen
US6127353A (en)	1991-09-06	2000-10-03	Schering Corporation	Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) *	1994-01-27	1998-11-17	Schering Corporation	Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) *	1994-01-27	1995-12-18	Schering Corp	Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US6068832A (en)	1996-08-29	2000-05-30	Schering Corporation	Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5837713A (en) *	1997-02-26	1998-11-17	Mayo Foundation For Medical Education And Research	Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6495167B2 (en) *	1997-03-20	2002-12-17	Schering Corporation	Preparation of powder agglomerates
US6503537B2 (en) *	1997-03-20	2003-01-07	Schering Corporation	Preparation of powder agglomerates
US6187765B1 (en)	1997-10-09	2001-02-13	Schering Corporation	Mometasone furoate suspensions for nebulization
US6297227B1 (en) *	1998-09-10	2001-10-02	Schering Corporation	Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
SE9803770D0 (sv) *	1998-11-05	1998-11-05	Astra Ab	Dry powder pharmaceutical formulation
US6465581B1 (en) *	2001-01-24	2002-10-15	The Goodyear Tire & Rubber Company	Silica reinforced rubber composition which contains stabilized unsymmetrical coupling agents and article of manufacture, including a tire, having at least one component comprised of such rubber composition
AR036358A1 (es) *	2001-08-28	2004-09-01	Schering Corp	Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
DE60311665T2 (de) *	2002-08-23	2007-10-25	Schering Corp.	Pharmazeutische zusammensetzungen
US20040081625A1 (en) *	2002-10-21	2004-04-29	Schering Corporation	Nasal formulations for the treatment of allergies
US8912174B2 (en) *	2003-04-16	2014-12-16	Mylan Pharmaceuticals Inc.	Formulations and methods for treating rhinosinusitis
US20040235807A1 (en) *	2003-05-21	2004-11-25	Weinrich Karl P.	Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
AU2004285447A1 (en) *	2003-10-20	2005-05-12	Schering Corporation	Pharmaceutical compositions
RS51335B (en) *	2004-01-21	2011-02-28	Schering Corporation	METHOD OF TREATMENT OF ACUTE RHINOSINUSITIS
WO2012082735A1 (en)	2010-12-13	2012-06-21	Nanostim, Inc.	Delivery catheter systems and methods
US9106249B1 (en)	2014-09-04	2015-08-11	Semtech Corporation	Calibration of a time-interleaved analog-to-digital converter

2005
- 2005-01-19 RS RSP-2010/0236A patent/RS51335B/en unknown
- 2005-01-19 AT AT05711867T patent/ATE461693T1/de active
- 2005-01-19 JP JP2006551345A patent/JP4976139B2/ja not_active Expired - Fee Related
- 2005-01-19 ES ES05711867T patent/ES2340777T3/es not_active Expired - Lifetime
- 2005-01-19 DE DE602005020113T patent/DE602005020113D1/de not_active Expired - Lifetime
- 2005-01-19 PL PL05711867T patent/PL1711164T3/pl unknown
- 2005-01-19 SI SI200531000T patent/SI1711164T1/sl unknown
- 2005-01-19 MX MXPA06008240A patent/MXPA06008240A/es active IP Right Grant
- 2005-01-19 PT PT05711867T patent/PT1711164E/pt unknown
- 2005-01-19 EP EP10003076.6A patent/EP2201936B1/en not_active Revoked
- 2005-01-19 EP EP05711867A patent/EP1711164B1/en not_active Expired - Lifetime
- 2005-01-19 CA CA002554064A patent/CA2554064A1/en not_active Abandoned
- 2005-01-19 ES ES10003076T patent/ES2426957T3/es not_active Expired - Lifetime
- 2005-01-19 DK DK05711867.1T patent/DK1711164T3/da active
- 2005-01-19 WO PCT/US2005/002105 patent/WO2005072704A2/en active Application Filing
- 2005-01-19 US US11/038,343 patent/US20050186144A1/en not_active Abandoned
2008
- 2008-01-28 JP JP2008016970A patent/JP2008110991A/ja active Pending
- 2008-07-11 US US12/171,989 patent/US20090022671A1/en not_active Abandoned
2010
- 2010-04-13 HR HR20100208T patent/HRP20100208T8/xx unknown
- 2010-04-28 CY CY20101100378T patent/CY1110620T1/el unknown

Also Published As

Publication number	Publication date
PL1711164T3 (pl)	2010-09-30
WO2005072704A3 (en)	2006-07-20
EP2201936A1 (en)	2010-06-30
CA2554064A1 (en)	2005-08-11
RS51335B (en)	2011-02-28
JP4976139B2 (ja)	2012-07-18
EP1711164A2 (en)	2006-10-18
ES2426957T3 (es)	2013-10-28
JP2008110991A (ja)	2008-05-15
JP2007518817A (ja)	2007-07-12
HRP20100208T1 (hr)	2010-05-31
ATE461693T1 (de)	2010-04-15
US20090022671A1 (en)	2009-01-22
EP1711164B1 (en)	2010-03-24
DE602005020113D1 (de)	2010-05-06
PT1711164E (pt)	2010-06-28
EP2201936B1 (en)	2013-06-19
CY1110620T1 (el)	2015-04-29
SI1711164T1 (sl)	2010-06-30
WO2005072704A2 (en)	2005-08-11
US20050186144A1 (en)	2005-08-25
HRP20100208T8 (en)	2010-06-30
ES2340777T3 (es)	2010-06-09
MXPA06008240A (es)	2006-08-31

Publication	Publication Date	Title
NO2018030I1 (no)	2018-09-11	Florbetapir (18F)
CY1110620T1 (el)	2015-04-29	Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
ATE530519T1 (de)	2011-11-15	Cyclobutylaminderivate
WO2006085149A3 (en)	2007-05-10	Methods and compositions for treating amyloid-related diseases
TW200738270A (en)	2007-10-16	Method of treating depression using a TNFα antibody
DK1984357T3 (da)	2014-01-13	2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
NO20072035L (no)	2007-06-13	Memantin for behandling av adferdsforstyrrelser hos barn
NO345046B1 (no)	2020-09-07	Oral doseringsform
LTC1781298I2 (lt)	2018-09-25	Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
WO2006078463A3 (en)	2007-05-31	Method for treating cardiovascular disease
CY1112889T1 (el)	2016-04-13	Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
NO20082473L (no)	2008-08-06	Fremgangsmater, sammensetninger og sett for behandling av medisinske tilstander
BRPI0814939A2 (pt)	2015-01-27	Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
BRPI0606112A2 (pt)	2009-06-02	3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
EP2023926A4 (en)	2010-08-04	PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
BRPI0515372A (pt)	2008-07-22	composição, e, método para fornecer um efeito anestésico a um sìtio em um indivìduo
WO2008134724A3 (en)	2009-02-12	Methods for administering anti-il-5 antibodies
WO2007100901A3 (en)	2008-10-16	Epinephrine dosing regimens
PT2383271E (pt)	2013-10-10	Aminoquinolonas como inibidores de gsk-3
SMT201200014B (it)	2012-07-10	Nalmefene cloridrato diidrato.
NO20075111L (no)	2007-11-16	Farmasoytisk sammensetning
CY1112727T1 (el)	2016-02-10	Παραγωγα κυκλοβουτυλ αμινης βενζοθειαζολης και η χρηση αυτων ως προσδετες των υποδοχεων ισταμινης-3
ATE449096T1 (de)	2009-12-15	Verfahren zur herstellung von 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-p enoxypropyl)-1- azoniabicycloä2.2.2üoctanbromid
HK1097774A1 (en)	2007-07-06	Stable pharmaceutical composition comprising linezolid from iv
BRPI0716375A2 (pt)	2013-10-15	Método para reduzir ou inibir depressão respiratória em um sujeito; método para induzir analgesia, anestesia ou sedação em um sujeito, reduzindo ou inibindo simultaneamente depressão respiratória no sujeito; e composição farmacêutica para induzir analgesia, anestesia ou sedação em um sujeito...